Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

Pietro Annovazzi, M. Capobianco, L. Moiola, F. Patti, J. Frau, A. Uccelli, D. Centonze, P. Perini, C. Tortorella, L. Prosperini, G. Lus, A. Fuiani, M. Falcini, V. Martinelli, Giancarlo Comi, A. Ghezzi

Research output: Contribution to journalArticle

Abstract

Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7–106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08–4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.
Original languageEnglish
Pages (from-to)1727 - 1735
Number of pages9
JournalJournal of Neurology
Volume263
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Neuromyelitis Optica
Observational Studies
Therapeutics
Rituximab
Recurrence

Keywords

  • Devic’s syndrome
  • Dosing regimen
  • Neuromyelitis optica
  • Rituximab

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. / Annovazzi, Pietro; Capobianco, M.; Moiola, L.; Patti, F.; Frau, J.; Uccelli, A.; Centonze, D.; Perini, P.; Tortorella, C.; Prosperini, L.; Lus, G.; Fuiani, A.; Falcini, M.; Martinelli, V.; Comi, Giancarlo; Ghezzi, A.

In: Journal of Neurology, Vol. 263, No. 9, 01.09.2016, p. 1727 - 1735.

Research output: Contribution to journalArticle

Annovazzi, P, Capobianco, M, Moiola, L, Patti, F, Frau, J, Uccelli, A, Centonze, D, Perini, P, Tortorella, C, Prosperini, L, Lus, G, Fuiani, A, Falcini, M, Martinelli, V, Comi, G & Ghezzi, A 2016, 'Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study', Journal of Neurology, vol. 263, no. 9, pp. 1727 - 1735. https://doi.org/10.1007/s00415-016-8188-y
Annovazzi, Pietro ; Capobianco, M. ; Moiola, L. ; Patti, F. ; Frau, J. ; Uccelli, A. ; Centonze, D. ; Perini, P. ; Tortorella, C. ; Prosperini, L. ; Lus, G. ; Fuiani, A. ; Falcini, M. ; Martinelli, V. ; Comi, Giancarlo ; Ghezzi, A. / Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. In: Journal of Neurology. 2016 ; Vol. 263, No. 9. pp. 1727 - 1735.
@article{30a31c23f6bc4775a4da12b39d3eeb36,
title = "Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study",
abstract = "Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7–106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 {\%} IC 1.08–4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.",
keywords = "Devic’s syndrome, Dosing regimen, Neuromyelitis optica, Rituximab",
author = "Pietro Annovazzi and M. Capobianco and L. Moiola and F. Patti and J. Frau and A. Uccelli and D. Centonze and P. Perini and C. Tortorella and L. Prosperini and G. Lus and A. Fuiani and M. Falcini and V. Martinelli and Giancarlo Comi and A. Ghezzi",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00415-016-8188-y",
language = "English",
volume = "263",
pages = "1727 -- 1735",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "9",

}

TY - JOUR

T1 - Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

AU - Annovazzi, Pietro

AU - Capobianco, M.

AU - Moiola, L.

AU - Patti, F.

AU - Frau, J.

AU - Uccelli, A.

AU - Centonze, D.

AU - Perini, P.

AU - Tortorella, C.

AU - Prosperini, L.

AU - Lus, G.

AU - Fuiani, A.

AU - Falcini, M.

AU - Martinelli, V.

AU - Comi, Giancarlo

AU - Ghezzi, A.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7–106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08–4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.

AB - Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7–106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08–4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.

KW - Devic’s syndrome

KW - Dosing regimen

KW - Neuromyelitis optica

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84973665403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973665403&partnerID=8YFLogxK

U2 - 10.1007/s00415-016-8188-y

DO - 10.1007/s00415-016-8188-y

M3 - Article

VL - 263

SP - 1727

EP - 1735

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 9

ER -